Cardiome Pharma Corp. (USA) (NASDAQ:CRME)
Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
It gets a 6-2 vote in favor and sells off. I don't really understand, but think that it will head back into the double digits...
Recs
Clinical studies very positive for conversion of Atrial
Fibrillation. Side-effect profile benign. Currently with
intravenous formulation, awaiting oral clinical studies.
Very lucrative upside if recommended by FDA
committee in January.
Recs
It would be hard to go against what all have said, dark horse, speculative, takeover candidate, needs successful clinical trials, reasonable entry point.
Put your money down and roll.....
Recs
Speculative play in biotech
Recs
dark horse with great buy in price...
Recs
Poor company in the sector.
Recs
IV agent for atrial fib is best in class and will be approved. Oral agent has great promise
Recs
Successful clinical trials with new drug to treat atrial fibrillation. May be a takeover candidate.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 21 - 28 of 28 : « Previous 1 2